Case Report

Multimodal Imaging in Diagnosing Multiple Evanescent White Dot Syndrome following Human Papillomavirus Vaccine Immunization

Jing Yu,1,2 Yuying Ji,3 Yunkao Zeng,4 Huihui Li,1,2 Hailan Liao,1,2 and Feng Wen3

1Ophthalmology Department of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
2Longgang District People’s Hospital of Shenzhen, Shenzhen 518172, China
3State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
4Department of Ophthalmology, The Second Affiliated Hospital of Guangzhou Medical University, No. 250 Changgang East Road, Haizhu District, Guangzhou City 510260, China

Correspondence should be addressed to Feng Wen; wenfeng208@foxmail.com

Received 26 July 2023; Revised 6 December 2023; Accepted 22 December 2023; Published 19 January 2024

Academic Editor: Alexander Bialasiewicz

Copyright © 2024 Jing Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. This study presents a case of multiple evanescent white dot syndrome (MEWDS) following the administration of the second dose of a human papillomavirus vaccine (HPV). We conducted a review of the literature on vaccine-associated MEWDS. Observations. A 23-year-old Chinese female reported central scotomata in the left eye persisting for 3 weeks. Upon further inquiry, she had received the second dose of the human papillomavirus vaccine (Gardasil-9) three days before the onset of symptoms. A diagnosis of MEWDS was established based on clinical and multimodal imaging (MMI) data. Symptoms resolved after twelve weeks of oral prednisone treatment. Conclusion and Importance. This case highlights a typical case of MEWDS closely associated with HPV vaccination, demonstrating a favorable prognosis with MMI. Given the self-limiting nature of MEWDS, there is a risk of clinical misdiagnosis or oversight. While further studies are warranted to establish a definitive link between the HPV vaccine and MEWDS, this case suggests a potential connection. Healthcare practitioners should remain vigilant regarding possible ocular side effects associated with immunizations.

1. Introduction

While uncommon, there have been accumulating reports of vaccine-associated uveitis as a local adverse effect of vaccinations [1]. Cases of multiple evanescent white dot syndrome (MEWDS) have been documented following various vaccinations [2], with a notable increase in reports associated with the introduction of COVID-19 vaccines. This study presents a case of MEWDS following the administration of the second dose of a human papillomavirus vaccine. Additionally, we conducted a comprehensive review of all reported cases of vaccine-associated MEWDS and compared the findings.

2. Case Report

We report the case of a 23-year-old Chinese female who presented with central scotomata in her left eye (OS) persisting for three weeks. Initially diagnosed with xerophthalmia at a local hospital, her symptoms did not improve with sodium hyaluronate eye drop treatment. Subsequently, she sought evaluation at the Zhongshan Ophthalmic Center of Sun Yat-sen University. Upon ophthalmic examination, her OD (right eye) exhibited a best-corrected visual acuity (BCVA) of 15/100, while her OS (left eye) demonstrated a BCVA of 20/20 with refractive errors of +2.50DS/-0.25DC155 and...
-5.00DS/-1.25DC170, respectively. Intraocular pressure measured 11 mmHg in both eyes, and extraocular motility was normal. Pupils were evenly rounded and responsive to light. Slit-lamp examination revealed normal anterior segments and vitreous. A tessellated fundus was also observed (OS) (Figure 1(a)). Fundus autofluorescence (FAF) exhibited numerous mixed hyperfluorescent patches, dispersed hyperfluorescent lesions, and small hyperfluorescent circles, all centered around the optic disc and posterior pole (OS) (Figure 1(b)). Optical coherence tomography (OCT) revealed diffuse damage in the ellipsoid zone (EZ) near the macula and punctate hyperreflective lesions of varying sizes in the outer retina (Figure 1(d)). Fluorescein angiography (FA) depicted early punctate hyperfluorescence in a wreath-like pattern with late staining (Figure 1(c)). The diagnosis of MEWDS was established based on the clinical and multimodal imaging (MMI) data. Upon further inquiry, the patient reported receiving the second dose of a human papillomavirus (HPV) vaccine (Gardasil-9) three days before the onset of symptoms. The patient denied experiencing flu-like symptoms and had a history of amblyopia in the right eye, with no remarkable past medical or family histories.

A trial of prednisone 20 mg per day was administered for 1 week and then tapered gradually. Four weeks later, she said the central scotomata were getting better. In FAF, there were less hyperfluorescent spots (Figure 2(a)). OCT findings demonstrated improved EZ and less punctate hyperreflective lesions in the left (Figure 2(b)). Her BCVA was 0.15 (15/100) on the right and 1.0(20/20) on the left at that time. Twelve weeks after the initial presentation, she said the central scotomata had already disappeared. In addition, the hyperfluorescent spots in FAF disappeared completely (Figure 3(a)). OCT demonstrated EZ recovery in OS (Figure 3(b)).

3. Discussion

MEWDS, initially described by Jampol et al. in 1984 [3], is a relatively uncommon condition characterized by the unilateral presence of numerous pale yellow lesions in the outer retina and retinal pigment epithelium, often accompanied
by foveal orange granularity. Typically affecting young individuals, particularly women [4], up to 50% of MEWDS cases may exhibit flu-like symptoms preceding ocular involvement. The condition has been associated with influenza and various immunizations, and in most instances, spontaneous resolution occurs within 8 to 10 weeks [5].

In this case, it is highly conceivable that the patient was initially misdiagnosed, leading to an absence of recorded fundus data during the early stages. When she presented at Zhongshan Ophthalmic Center, no specific fundus changes were noted. However, subsequent clinical and multimodal imaging findings supported the diagnosis of MEWDS. The patient, a previously healthy young woman, developed a central scotoma in her myopic eye (OS) three days after receiving an HPV vaccination. The clinical characteristics and MMI results aligned with MEWDS. HPV vaccines, given as preventative measures, are an affordable technique that can lower the incidence of cervical cancer. Gardasil-9, licensed by the FDA in 2014, provides defense against HPV6, 11, 16, 18, 31, 33, 45, and 58 (Merck & Co., Kenilworth, NJ, USA). It has been reported that Gardasil-9 has the potential to prevent almost 90% of cervical cancers due to the five new types it covers, which could include HPV strains linked to an additional 20% of occurrences of cervical cancer [6]. The HPV vaccine is administered in three doses over the course of a series [7].

Two studies have discussed the incidence of MEWDS following HPV vaccination [8, 9]. In one study, a 16-year-old girl developed throat soreness, headache, and photopsia (OS) two weeks after her second HPV shot (Cervarix®, Glaxo Smith Kline). Two months later, the white dots had mostly vanished, but the patient’s visual field had deteriorated, and she reported losing her peripheral vision gradually over a two-year period. The authors explored the possibility of a coexisting disease entity, such as acute zonal occult outer retinopathy. In the other study, a previously healthy 17-year-old girl with myopia reported seeing dark shimmering spots (OS) for three days. Only her left eye was affected. She had received her first meningococcal and HPV vaccinations one month before the onset of vision loss, which resolved without treatment in eight weeks.

**Figure 2**: Four weeks later, (a) FAF has less hyperfluorescent spots. (b) OCT findings demonstrated improved EZ and less punctate hyperreflective lesions.
Ng et al. reported a median duration of 14 days (range: 1-30 days) between immunization and MEWDS [2]. Despite most MEWDS cases having an infectious trigger before ocular symptoms emerge, our patient received the second dose of the HPV vaccine merely three days before symptom onset, suggesting the probable role of ocular inflammation induced by vaccination in this MEWDS case. In contrast to the previous two cases, we present the first instance of MEWDS after the nine-valent HPV vaccination, with multimodal imaging findings. The nine-valent vaccine, containing more target proteins and virus-like particles, covering additional HPV subtypes, and incorporating more adjuvants, potentially increases the likelihood of adverse events in patients [6]. Our patient’s vaccination was more temporally relevant to MEWDS onset. In contrast to a previous case with a good prognosis who received both meningococcal and HPV vaccines, our patient, receiving only the HPV vaccine, also experienced a good prognosis. Another case that received only the HPV vaccine, however, showed a poor prognosis, and the possibility of a different concurrent disease entity should have been considered by the authors.

Over the years, several MEWDS cases have recovered following vaccination with various medications. The COVID-19 outbreak has led to the development of different vaccines, and some cases of MEWDS have been reported after COVID-19 vaccination. We have summarized and compared all the cases in Table 1.

There have been twenty-four published MEWDS cases after different vaccines, including rabies [10], human papillomavirus [8, 9], hepatitis A [11], hepatitis B [12], meningococcal [9], yellow fever [13], influenza [14], and COVID-19 [15–25]. Patients with postvaccination MEWDS were mostly healthy (79.2%), youthful to middle-aged (mean 35.9 years; median 33.5 years; range 15–71 years) women (66.7%). 91.7% of patients received the inactive vaccine. Symptoms manifested on average 11.1 days (median: 8.5; range: 1-30) after immunization. Mean presenting the Snellen visual acuity was of 20/34 (median: 20/30; range: 20/400-20/16). A spontaneous return to baseline Snellen visual acuity was seen in seventeen cases (70.8%) of postvaccine MEWDS after an average of 5.9 weeks (median: 6 weeks; range: 2-12 weeks). Ten cases (41.6%) of MEWDS developed after receiving the second or the third dose of vaccination.

According to Bolletta et al. [23], 58.8% of ocular problems caused by COVID-19 immunization were discovered after the second dosage. Renisi et al. [26] found that while local reactogenicity was similar for both vaccine dosages, systemic reactogenicity was more prevalent and severe after the second dose. The US Centers for Disease Control and Prevention (CDC) cautioned that the second dose of the BNT162b2 vaccine is linked to an increased risk of adverse effects throughout the body. In one study [27], roughly 60% of recipients reported experiencing symptoms such as fever, headache, myalgia, and general malaise following the second dose. Uveitis following the second dose of the COVID-19 vaccine may occur, as observed in this case, indicating a possible connection between immunization and MEWDS. Different vaccines may have common pathogenesis, and several articles on molecular mimicry [28], hypersensitivity reactions [29], and autoimmunity induced by adjuvants (ASIA) [30] have been written to illustrate this phenomenon. Nevertheless, establishing a definitive link between the vaccine and MEWDS proved challenging, and it remains possible that the eye irritation following immunization was a coincidence.

The potential pathogenesis of the patient’s condition may have been as follows: after the initial vaccination dose, the body became sensitized and produced a small amount of antibodies. With the second dose, the antigen-antibody reaction intensified. Additionally, myopia may have contributed to a thinner retinal pigment epithelium, potentially allowing antibodies to reach the photoreceptor and cause MEWDS. The patient’s immune function may also have played a role in MEWDS development.

Figure 3: Twelve weeks later, compared with the initial presentation, (a) the hyperfluorescent spots in FAF disappeared completely. (b) OCT demonstrated EZ recovery.
**Table 1: Summary of all cases of MEWDS following vaccination.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Vaccine name</th>
<th>Age</th>
<th>Gender</th>
<th>Time from vaccination (days)</th>
<th>Vaccine type</th>
<th>Comorbidities</th>
<th>Presenting VA in affected eye (Snellen)</th>
<th>Vision at last visit in the affected eye</th>
<th>Intervention</th>
<th>Time until resolution (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baglivo et al. [10]</td>
<td>Hepatitis B booster 3rd dose</td>
<td>23</td>
<td>F</td>
<td>1</td>
<td>Recombinant vaccines</td>
<td>None</td>
<td>20/200</td>
<td>Undisclosed-“recovery of vision”</td>
<td>None</td>
<td>12</td>
</tr>
<tr>
<td>Fine et al. [11]</td>
<td>Hepatitis A</td>
<td>33</td>
<td>M</td>
<td>13</td>
<td>Inactivated vaccines</td>
<td>None</td>
<td>20/25-2</td>
<td>20/20</td>
<td>None</td>
<td>6</td>
</tr>
<tr>
<td>Stangos et al. [12]</td>
<td>Hepatitis A and yellow fever</td>
<td>50</td>
<td>F</td>
<td>10</td>
<td>Inactivated vaccines</td>
<td>None</td>
<td>20/40</td>
<td>20/20</td>
<td>None</td>
<td>6</td>
</tr>
<tr>
<td>Cohen [9]</td>
<td>Human papilloma virus and meningococca</td>
<td>17</td>
<td>F</td>
<td>30</td>
<td>Recombinant vaccines</td>
<td>None</td>
<td>20/200</td>
<td>20/20</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td>Goyal et al. [13]</td>
<td>Influenza</td>
<td>53</td>
<td>M</td>
<td>10</td>
<td>Undisclosed</td>
<td>Hepatitis B and C infection, polysubstance abuse</td>
<td>20/25-2</td>
<td>20/20</td>
<td>None</td>
<td>4</td>
</tr>
<tr>
<td>Ogino et al. [8]</td>
<td>Human papilloma virus (Cervarix®, Glaxo Smith Kline) 2nd dose</td>
<td>16</td>
<td>F</td>
<td>14</td>
<td>Recombinant vaccines</td>
<td>None</td>
<td>20/16</td>
<td>20/16</td>
<td>None initially, betamethasone and antihistamine later for peripheral vascular leakage and associated visual field constriction</td>
<td>Retinal lesions resolved at 2 months; worsening peripheral vision loss for 2 years</td>
</tr>
<tr>
<td>Abou-Samra et al. [14]</td>
<td>Influenza</td>
<td>27</td>
<td>F</td>
<td>14</td>
<td>Undisclosed</td>
<td>Stevens-Johnson syndrome, Wolff-Parkinson-White, vesicourethral reflux, mild chronic kidney disease, endometriosis, fibroadenomas, depression with anxiety</td>
<td>20/25-2</td>
<td>Undisclosed</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td>Yang et al. [15]</td>
<td>Rabies 3rd dose</td>
<td>33</td>
<td>F</td>
<td>14</td>
<td>Embryonated-egg vaccine</td>
<td>None</td>
<td>20/20</td>
<td>20/20</td>
<td>Retrobulbar triamcinolone acetonide 40 mg</td>
<td>Partially resolved at 8 weeks</td>
</tr>
<tr>
<td>Ng et al. [2]</td>
<td>Influenza (Flucelvax Quadrivalent® Seqirus)</td>
<td>34</td>
<td>M</td>
<td>14</td>
<td>Inactivated vaccines</td>
<td>None</td>
<td>20/20+2</td>
<td>20/16</td>
<td>None</td>
<td>4</td>
</tr>
<tr>
<td>Study</td>
<td>Vaccine name</td>
<td>Age</td>
<td>Gender</td>
<td>Time from vaccination (days)</td>
<td>Vaccine type</td>
<td>Comorbidities</td>
<td>Presenting VA in affected eye (Snellen)</td>
<td>Vision at last visit in the affected eye</td>
<td>Intervention</td>
<td>Time until resolution (weeks)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------</td>
<td>------</td>
<td>--------</td>
<td>-------------------------------</td>
<td>------------------------------</td>
<td>---------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Rabinovitch et al. [16]</td>
<td>COVID-19 2nd dose</td>
<td>39</td>
<td>M</td>
<td>5</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/32</td>
<td>20/20</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>28</td>
<td>F</td>
<td>30</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/32</td>
<td>20/20</td>
<td>None</td>
<td>8</td>
</tr>
<tr>
<td>Xu and Shen [17]</td>
<td>COVID-19 1st dose</td>
<td>49</td>
<td>F</td>
<td>2</td>
<td>Inactivated vaccines</td>
<td>MEWDS</td>
<td>20/100</td>
<td>20/20</td>
<td>Oral prednisone</td>
<td>8</td>
</tr>
<tr>
<td>Inagawa et al. [18]</td>
<td>COVID-19 1st dose</td>
<td>30</td>
<td>F</td>
<td>6</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/20</td>
<td>20/20</td>
<td>Topical corticosteroid</td>
<td>8</td>
</tr>
<tr>
<td>Yasuda et al. [19]</td>
<td>COVID-19 2nd dose</td>
<td>67</td>
<td>F</td>
<td>1</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/100</td>
<td>20/25</td>
<td>None</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36</td>
<td>F</td>
<td>2</td>
<td>Recombinant vaccines</td>
<td>None</td>
<td>20/25</td>
<td>20/20</td>
<td>None</td>
<td>4</td>
</tr>
<tr>
<td>Tomishige et al. [21]</td>
<td>COVID-19 1st dose</td>
<td>38</td>
<td>F</td>
<td>7</td>
<td>Inactivated vaccines</td>
<td>None</td>
<td>20/400</td>
<td>20/20</td>
<td>Oral prednisone</td>
<td>4</td>
</tr>
<tr>
<td>Smith et al. [22]</td>
<td>COVID-19 2nd dose</td>
<td>15</td>
<td>M</td>
<td>14</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/100</td>
<td>20/20</td>
<td>Oral prednisone</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21</td>
<td>F</td>
<td>21</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/60</td>
<td>20/20</td>
<td>Oral prednisone</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>COVID-19 2nd dose</td>
<td>53</td>
<td>M</td>
<td>28</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/25</td>
<td>20/20</td>
<td>None</td>
<td>Undisclosed time but complete resolution</td>
</tr>
<tr>
<td>Bolletta et al. [23]</td>
<td>COVID-19 1st dose</td>
<td>18</td>
<td>F</td>
<td>4</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/66</td>
<td>20/20</td>
<td>None</td>
<td>Undisclosed time but complete resolution</td>
</tr>
<tr>
<td></td>
<td>COVID-19 1st dose</td>
<td>48</td>
<td>M</td>
<td>7</td>
<td>mRNA vaccines</td>
<td>None</td>
<td>20/400</td>
<td>20/20</td>
<td>None</td>
<td>Undisclosed time but complete resolution</td>
</tr>
<tr>
<td>Alhabshan and Scales [24]</td>
<td>COVID-19 3rd dose</td>
<td>71</td>
<td>F</td>
<td>3</td>
<td>mRNA vaccines</td>
<td>Retinal tear was treated with laser barricade; hysterectomy, hypercholesterolemia</td>
<td>20/30</td>
<td>Undisclosed</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Case Reports in Ophthalmological Medicine
<table>
<thead>
<tr>
<th>Vaccine name</th>
<th>Age</th>
<th>Gender</th>
<th>Time from vaccination (days)</th>
<th>Vaccine type</th>
<th>Comorbidities</th>
<th>Presenting VA in affected eye (Snellen)</th>
<th>Vision at last visit in the affected eye (Snellen)</th>
<th>Time until resolution (weeks)</th>
<th>Vaccine that developed after Delta variant?</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 1st dose</td>
<td>23 F</td>
<td>10 mRNA vaccines SARS-CoV-2 infection</td>
<td>20/20</td>
<td>20/20</td>
<td>None</td>
<td>6</td>
<td>Mean: 35.9</td>
<td>Median: 33.5</td>
<td>Range: 15 – 71</td>
<td>91.7%</td>
</tr>
<tr>
<td>None</td>
<td>7 M</td>
<td>mRNA vaccines SARS-CoV-2 infection</td>
<td>20/25</td>
<td>20/20</td>
<td>None</td>
<td>6</td>
<td>Mean: 11.1</td>
<td>Median: 8.5</td>
<td>Range: 1 – 30</td>
<td>91.7%</td>
</tr>
</tbody>
</table>

Table 1: Continued.
4. Conclusions

Overall, the relationship between the HPV vaccine and MEWDS warrants further study. Vaccines may cause MEWDS by inducing an autoimmune response. Prophylactic vaccinations against concomitant disorders have proven to be the most cost-effective techniques for lowering disease incidence. Since the advent of the smallpox vaccine, humans have benefited greatly from various vaccinations. Despite their rarity and minimal likelihood of adverse effects, the advantages of vaccinations exceed the risks. Indeed, doctors should be aware of any potential ocular side effects from such immunizations.

Data Availability

Data are available on request.

Ethical Approval

For this type of study, ethical approval is not required. The article is written according to the World Medical Association Declaration of Helsinki.

Consent

No written consent has been obtained from the patients as there is no patient-identifiable data included in this case.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

JY, Yy-J, and FW analyzed and interpreted the patient data and were a major contributor in writing the manuscript. Yk-Z, Hh-L, and Hl-L were major contributors in writing the manuscript. All authors read and approved the final manuscript. Jing Yu and Yuying Ji contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (grant number: 82070970) and the Fundamental Research Funds of State Key Laboratory of Ophthalmology.

References


[28] A. Vojdani and K. DJCi, "Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases," *Clinical Immunology*, vol. 217, article 108480, 2020.
